

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	rotigotine
Brand Name	Neupro®
Dosage Form(s)	2 mg/24 hr, 4 mg/24 hr, 6 mg/24 hr and 8 mg/24 hr transdermal system (patch)
Manufacturer	UCB Canada Inc.
Submission Review	New Submission
Use Reviewed	Treatment of idiopathic Parkinson Disease (PD)
Common Drug Review (CDR)	CDR recommended not to list rotigotin. Visit CDR website for more details: http://www.cadth.ca/media/cdr/complete/SR0344_complete_Neupro_May-30-14.pdf
Drug Benefit Council (DBC)	No
Drug Coverage Decision	Non-Benefit
Date	November 18, 2014
Reason(s)	<ul style="list-style-type: none"> • Rotigotine was submitted by the manufacturer for the treatment of early idiopathic PD (EPD) as monotherapy and treatment of advanced idiopathic PD (APD) in combination with levodopa with similar listing criteria as pramipexole and ropinirole. • CDR recommended not to list rotigotine because clinical evidence failed to consistently demonstrate that rotigotine is non-inferior to pramipexole and ropinirole. • At the submitted price, rotigotine is more costly than pramipexole and ropinirol. • CDR considered the route of administration for rotigotine and noted that there was insufficient data to confirm the benefit of transdermal administration compared to oral administration with respect to patient adherence and clinical endpoints. • Rotigotin was not reviewed by the DBC because it received a 'Do Not List' recommendation from the CDR.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) gives advice to the Ministry. The Council looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C. and the drugs cost
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the Council
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, please visit
<http://www.health.gov.bc.ca/pharmacare/outgoing/drugrevproc2.pdf>.

To find out more about the Pharmaceutical Services Division and the PharmaCare program, visit
www.health.gov.bc.ca/pharmacare.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.